Sapien 3 Ultra balloon-expandable transcatheter aortic valve: in-hospital and 30-day results from the multicentre S3U registry.
To evaluate 30-day safety and efficacy outcomes of transcatheter aortic valve implantation (TAVI) performed with the SAPIEN 3 Ultra (Edwards Lifesciences, Irvine, CA) system. The S3U Registry is a physician-led, post-approval, multicenter, observational registry of transfemoral TAVI with the SAPIEN 3 Ultra. New features include an improved sealing skirt, a 14F expandable sheath and a new delivery catheter. Overall, 139 consecutive patients at 9 participating centers were enrolled. Mean age was 81.4±8.3 years, average STS score 3.8±2.4%. The vast majority (97.2%) underwent TAVI with local anesthesia (28.8%) or conscious sedation (68.3%). Balloon pre-dilatation was performed in 30 patients (21.6%), post-dilatation in 3 (2.2%). In-hospital, there were no cases of death, stroke, conversion to open-heart surgery. Major vascular complications occurred in 3 patients (2.2%), as well as major or life-threatening bleedings (2.2%). There were 2 moderate (1.4%) and no moderate/severe paravalvular leaks. Median length of stay after TAVI was 3 days (IQR 3-5 days). At 30-day there were no deaths, MI, or strokes and the incidence of new permanent pace-maker was 4.4%. This first multicenter international experience of transfemoral TAVI with the SAPIEN 3 Ultra transcatheter heart valve shows excellent in-hospital and 30-day clinical outcomes.